Related Experiment Video
Updated: Jan 18, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative
Yangyang Ou1, Yiyu Chen1, Kang Chen1
1Department of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530007, China.
Background:
Conversion therapy offers new hope for patients with unresectable hepatocellular carcinoma (uHCC), thereby becoming a pivotal advancement in the field of liver cancer treatment.
Methods:
This study consecutively collected clinical data of patients who received different conversion therapy regimens from June 2020 to March 2024, and retrospectively analyzed their efficacy and survival prognosis.
Results:
In this study, the conversion success rate of patients with uHCC after conversion therapy was 20.4 %. Patients who successfully converted had a better long-term prognosis than those who failed. Compared with patients treated with combination therapy, the conversion rate and objective response rate of single local treatment were lower.
Conclusions:
The choice of conversion therapy is crucial for the prognosis of patients with uHCC. The triple therapy of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with Tyrosine Kinase Inhibitor (TKI) and Immune Checkpoint Inhibitor (ICI) demonstrates favorable outcomes and manageable safety profiles.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...